ProCE Banner Activity


Genetic Alterations in Unresectable and Metastatic Biliary Tract Cancer: The Evolution of Targeted Therapy


This on-demand webcast aims to educate healthcare professionals about targeted therapy in patients with genetic alterations in metastatic and unresectable biliary tract cancer.  

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 05, 2024

Expiration: February 08, 2025



Mitesh J. Borad

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This program is intended for gastrointestinal oncologists involved in the diagnosis and management of patients with biliary tract cancer that are candidates for targeted systemic therapy.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge, confidence, and competence of the molecular testing for and therapeutic management of biliary tract cancer in patients that are candidates for targeted systemic therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Provide a detailed description of the known genomic alterations in BTC, the differences in their anatomical distribution and frequency, and their impact on disease progression

  • Select the appropriate molecular testing for individual patients with BTC and suspected genomic alterations, and explain the significance of the testing results to patients and their caregivers

  • Choose an appropriate targeted therapy based on the results of molecular testing for genomic alterations, and consider enrolling patients in clinical trials for alterations without an approved or off-label treatment option


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Mitesh J. Borad, MD: consultant/advisor/speaker: Merck, Servier; researcher: Relay.

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Lipika Goyal, MD, MPhil: consultant: AbbVie, AstraZeneca, Boehringer Ingelheim, Compass Therapeutics, Kinnate Biopharma, Merck, Servier, Taiho, TransThera Biosciences, Tyra Biosciences.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 05, 2024, through February 08, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.